Abstract: Polypeptides, nucleic acids, and compositions thereof are provided that include a targeting moiety. The polypeptides, nucleic acids, and compositions that comprise them, can be used in methods to treat subjects, to alter CAR-expressing cells in subjects who may suffer from a disease such as a cancer or a pathogen.

Abstract: The present disclosure relates to a method of modulating one or more genetically modified cells, e.g., chimeric antigen receptor (CAR)-expressing cells, ex vivo and/or in vivo.

Abstract: Methods and systems for the efficient and systematic identification of the repertoire of T-cell epitopes.

Abstract: A recombinant microorganism includes a transgene encoding a polypeptide of a Type II biotin synthase, wherein a holo-protein of the Type II biotin synthase comprises per polypeptide chain a first [4Fe—4S] cluster (radical SAM (RS) cluster) coordinated to a CxxxCxxC motif in the polypeptide chain and a second [4Fe—4S] cluster. The Type II biotin synthase contains a serine to cysteine swap in its holo-protein amino acid sequence, that is the amino acid at the position corresponding to Ser-43 in the E. coli K12 Type I biotin synthase holo-protein is a Cysteine and the amino acid corresponding to Cys-97 in the E. coli K12 Type I biotin synthase holo-protein is a Serine. A method for producing biotin includes cultivating the recombinant microorganism in a growth medium to produce a culture; and recovering biotin from the culture.

Abstract: Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided.

Abstract: This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.

Abstract: This disclosure relates to compositions and methods of identifying, isolating, and modulating cells and tissues based on their cellular glycosaminoglycan pattern. In some aspects, provided are anti-GAG motif antibodies or antigen-binding fragments thereof and their use for determining a glycosaminoglycan (GAG) glycotype for a cell. Also provided are methods of isolating cells, identifying cells, detecting a disease or disorder, and/or treating a disease or disorder based on a cellular glycotype.

Abstract: Methods and compositions are provided for inhibiting or treating a viral infection in a subject using cell-impermeable inhibitors of Akt, scramblase and/or a phosphatidylserine.

Abstract: The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Abstract: Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3?,4-didehydroribose.

Abstract: Disclosed are human Programmed Cell Death-1 (PD-1) receptor mutants having selectivity for PD-L1 compared to PD-L2, methods of obtaining the mutants, and uses of the mutants for treatment and imaging.

Abstract: Methods and systems for high-throughput Identification of receptor:ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

Abstract: Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.

Abstract: Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided.

Abstract: Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.

Abstract: Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

Abstract: Methods and compositions are provided for inhibiting or treating a viral infection in a subject using cell-impermeable inhibitors of Akt, scramblase and/or a phosphatidylserine.

Abstract: Methods and compositions for clonally inhibiting or clonally stimulating T-cells are provided.

Abstract: Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3?,4-didehydroribose.